title: Reversible posterior leucoencephalopathy syndrome in an elderly male on sunitinib therapy.
abstract: OBJECTIVE
  Reversible posterior leucoencephalopathy syndrome (RPLS) has been reported following the use of anti-vascular endothelial growth factor (VEGF) agents such as bevacizumab, sorafinib and sunitinib. In this report we present a case of RPLS that occurred in an elderly male on sunitinib therapy.
  
  
  METHODS
  Other case reports of sunitinib-induced RPLS were reviewed and causality assessment was carried out using the World Health Organization-Uppsala Monitoring Centre criteria and the Naranjo algorithm.
  
  
  RESULTS
  Only a few cases of sunitinib-induced RPLS had been reported previously and elevated blood pressure at presentation was common in most of the patients. Our case was clinically similar to the earlier reports and the adverse reaction had a 'probable' relationship with sunitinib intake.
  
  
  CONCLUSIONS
  Physicians should monitor and manage elevated blood pressure in patients with sunitinib-induced RPLS.
authors.affiliation: Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India. drbisu7@gmail.com
authors.forename: Biswa M
authors.initials: BM
authors.lastname: Padhy
authors.forename: Saravana P
authors.initials: SP
authors.lastname: Shanmugam
authors.forename: Yogendra K
authors.initials: YK
authors.lastname: Gupta
authors.forename: Aman
authors.initials: A
authors.lastname: Goyal
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D007211:Indoles / Q000009:adverse effects* / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D000077210:Sunitinib; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D000077210:Sunitinib